| http://www.w3.org/ns/prov#value | - Facing a need to improve success rates, Pfizer, like other large pharmaceutical companies, is redirecting its R&D strategy. ...We have sharpened the focus on certain key areas, emphasized strategic externalization, which includes select CRO partners as alliances for the future, additional biotech acquisitions and collaborations, and [are] also building a real strong network with academia, said M
|
